Clinical Trial Detail

NCT ID NCT04207255
Title Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Medical University of South Carolina
Indications

prostate adenocarcinoma

prostate cancer

Therapies

ABC294640 + Enzalutamide

ABC294640 + Abiraterone

Age Groups: adult senior

No variant requirements are available.